Fulgent Genetic (FLGT) Upgraded to “Hold” at Zacks Investment Research

Fulgent Genetic (NASDAQ:FLGT) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research note issued on Monday.

According to Zacks, “Fulgent Genetics, Inc. is a technology company. It provide genetic testing services to physicians with clinically actionable diagnostic information. The Company’s technology platform integrates data comparison and suppression algorithms, adaptive learning software, advanced genetic diagnostics tools and integrated laboratory process which serves primarily to hospitals and medical institutions. Fulgent Genetics, Inc. is headquartered in Temple City, California. “

A number of other research firms also recently weighed in on FLGT. Credit Suisse Group reduced their target price on Fulgent Genetic from $11.00 to $10.00 and set an “outperform” rating on the stock in a report on Tuesday, August 8th. Piper Jaffray Companies reiterated an “overweight” rating and set a $7.00 target price (down previously from $10.00) on shares of Fulgent Genetic in a report on Wednesday, August 9th. Finally, ValuEngine upgraded Fulgent Genetic from a “sell” rating to a “hold” rating in a report on Monday, October 2nd. Two equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. The stock has an average rating of “Buy” and an average price target of $10.67.

Shares of Fulgent Genetic (NASDAQ FLGT) traded down 1.67% on Monday, reaching $4.71. The company’s stock had a trading volume of 13,502 shares. The company’s 50 day moving average price is $4.90 and its 200 day moving average price is $4.90. The company’s market cap is $83.56 million. Fulgent Genetic has a 12-month low of $4.37 and a 12-month high of $13.90.

Fulgent Genetic (NASDAQ:FLGT) last posted its earnings results on Monday, August 7th. The company reported $0.02 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.02. Fulgent Genetic had a negative return on equity of 0.02% and a negative net margin of 0.42%. The firm had revenue of $4.64 million for the quarter, compared to the consensus estimate of $5.03 million. Analysts forecast that Fulgent Genetic will post $0.14 EPS for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: This article was first published by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are viewing this article on another domain, it was illegally stolen and reposted in violation of international copyright laws. The original version of this article can be accessed at https://ledgergazette.com/2017/10/09/fulgent-genetic-flgt-upgraded-to-hold-at-zacks-investment-research-2.html.

In other Fulgent Genetic news, CFO Paul Kim sold 6,134 shares of the company’s stock in a transaction that occurred on Friday, August 11th. The stock was sold at an average price of $5.71, for a total transaction of $35,025.14. Following the transaction, the chief financial officer now owns 388,602 shares in the company, valued at approximately $2,218,917.42. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Institutional investors have recently bought and sold shares of the stock. Wells Fargo & Company MN grew its stake in shares of Fulgent Genetic by 2,046.0% in the 1st quarter. Wells Fargo & Company MN now owns 10,730 shares of the company’s stock worth $118,000 after buying an additional 10,230 shares during the last quarter. Bank of New York Mellon Corp purchased a new stake in shares of Fulgent Genetic in the 1st quarter worth approximately $122,000. Blair William & Co. IL purchased a new stake in shares of Fulgent Genetic in the 1st quarter worth approximately $287,000. Finally, William Blair Investment Management LLC grew its stake in shares of Fulgent Genetic by 10.4% in the 2nd quarter. William Blair Investment Management LLC now owns 640,219 shares of the company’s stock worth $4,091,000 after buying an additional 60,508 shares during the last quarter. Institutional investors own 16.78% of the company’s stock.

Fulgent Genetic Company Profile

Fulgent Genetics, Inc is a technology company. The Company offers genetic testing to provide p

According to Zacks, “Fulgent Genetics, Inc. is a technology company. It provide genetic testing services to physicians with clinically actionable diagnostic information. The Company’s technology platform integrates data comparison and suppression algorithms, adaptive learning software, advanced genetic diagnostics tools and integrated laboratory process which serves primarily to hospitals and medical institutions. Fulgent Genetics, Inc. is headquartered in Temple City, California. “

A number of other research firms also recently weighed in on FLGT. Credit Suisse Group reduced their target price on Fulgent Genetic from $11.00 to $10.00 and set an “outperform” rating on the stock in a report on Tuesday, August 8th. Piper Jaffray Companies reiterated an “overweight” rating and set a $7.00 target price (down previously from $10.00) on shares of Fulgent Genetic in a report on Wednesday, August 9th. Finally, ValuEngine upgraded Fulgent Genetic from a “sell” rating to a “hold” rating in a report on Monday, October 2nd. Two equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. The stock has an average rating of “Buy” and an average price target of $10.67.

Shares of Fulgent Genetic (NASDAQ FLGT) traded down 1.67% on Monday, reaching $4.71. The company’s stock had a trading volume of 13,502 shares. The company’s 50 day moving average price is $4.90 and its 200 day moving average price is $4.90. The company’s market cap is $83.56 million. Fulgent Genetic has a 12-month low of $4.37 and a 12-month high of $13.90.

Fulgent Genetic (NASDAQ:FLGT) last posted its earnings results on Monday, August 7th. The company reported $0.02 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.02. Fulgent Genetic had a negative return on equity of 0.02% and a negative net margin of 0.42%. The firm had revenue of $4.64 million for the quarter, compared to the consensus estimate of $5.03 million. Analysts forecast that Fulgent Genetic will post $0.14 EPS for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: This article was first published by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are viewing this article on another domain, it was illegally stolen and reposted in violation of international copyright laws. The original version of this article can be accessed at https://ledgergazette.com/2017/10/09/fulgent-genetic-flgt-upgraded-to-hold-at-zacks-investment-research-2.html.

In other Fulgent Genetic news, CFO Paul Kim sold 6,134 shares of the company’s stock in a transaction that occurred on Friday, August 11th. The stock was sold at an average price of $5.71, for a total transaction of $35,025.14. Following the transaction, the chief financial officer now owns 388,602 shares in the company, valued at approximately $2,218,917.42. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Institutional investors have recently bought and sold shares of the stock. Wells Fargo & Company MN grew its stake in shares of Fulgent Genetic by 2,046.0% in the 1st quarter. Wells Fargo & Company MN now owns 10,730 shares of the company’s stock worth $118,000 after buying an additional 10,230 shares during the last quarter. Bank of New York Mellon Corp purchased a new stake in shares of Fulgent Genetic in the 1st quarter worth approximately $122,000. Blair William & Co. IL purchased a new stake in shares of Fulgent Genetic in the 1st quarter worth approximately $287,000. Finally, William Blair Investment Management LLC grew its stake in shares of Fulgent Genetic by 10.4% in the 2nd quarter. William Blair Investment Management LLC now owns 640,219 shares of the company’s stock worth $4,091,000 after buying an additional 60,508 shares during the last quarter. Institutional investors own 16.78% of the company’s stock.

Fulgent Genetic Company Profile

Fulgent Genetics, Inc is a technology company. The Company offers genetic testing to provide physicians with clinically actionable diagnostic information to improve quality of patient care. The Company has developed a technology platform that integrates data comparison and suppression algorithms, adaptive learning software, advanced genetic diagnostics tools and integrated laboratory processes.

Receive News & Ratings for Fulgent Genetic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fulgent Genetic and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply